NYSEAMERICAN:OCX - OncoCyte Stock Price, Forecast & News

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

OncoCyte Corp (NYSEAMERICAN:OCX) announced its earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.10). View OncoCyte's Earnings History.

OncoCyte is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for OncoCyte.

2 brokers have issued 12-month price objectives for OncoCyte's stock. Their forecasts range from $7.00 to $7.75. On average, they anticipate OncoCyte's share price to reach $7.38 in the next twelve months. This suggests a possible upside of 185.9% from the stock's current price. View Analyst Price Targets for OncoCyte.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte.

Media stories about OCX stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OncoCyte earned a daily sentiment score of 1.8 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for OncoCyte.

OncoCyte saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 1,160,000 shares, a decrease of 7.2% from the January 15th total of 1,250,000 shares. Based on an average daily trading volume, of 290,900 shares, the days-to-cover ratio is currently 4.0 days. Approximately 2.5% of the company's stock are sold short. View OncoCyte's Current Options Chain.

Some companies that are related to OncoCyte include Cel-Sci (CVM), Bellus Health (BLU), Oxford BioMedica (OXB), Pfenex (PFNX), Starpharma (SPL), Pfenex (PFNX), Biotest (BIO), Trillium Therapeutics (TRIL), TELIX Pharmaceutical (TLX), Rafael (RFL), Silence Therapeutics (SLN), ProMetic Life Sciences (PLI), IMV (IMV), Resverlogix (RVX) and Theratechnologies (TH).

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include Alibaba Group (BABA), BioTime (BTX), Anavex Life Sciences (AVXL), Geron (GERN), Alnylam Pharmaceuticals (ALNY), Progenics Pharmaceuticals (PGNX), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO), Novocure (NVCR) and Matinas BioPharma (MTNB).

OncoCyte's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (3.92%), State Street Corp (0.84%), Geode Capital Management LLC (0.60%), P.A.W. Capital Corp (0.48%), Penbrook Management LLC (0.34%) and Barclays PLC (0.33%). Company insiders that own OncoCyte stock include Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine and Thomas Alex Vetter. View Institutional Ownership Trends for OncoCyte.

OCX stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, AQR Capital Management LLC and Mesirow Financial Investment Management Inc.. View Insider Buying and Selling for OncoCyte.

OCX stock was acquired by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp, Penbrook Management LLC, Barclays PLC, Oxford Asset Management LLP, Virtu Financial LLC, State Street Corp, UBS Group AG and Geode Capital Management LLC. Company insiders that have bought OncoCyte stock in the last two years include Andrew Arno, Broadwood Partners, LP, Mitchell S Levine and Thomas Alex Vetter. View Insider Buying and Selling for OncoCyte.

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OCX stock can currently be purchased for approximately $2.58.

OncoCyte has a market capitalization of $134.09 million. OncoCyte employs 12 workers across the globe.View Additional Information About OncoCyte.

The official website for OncoCyte is http://www.oncocyte.com/.

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.